claims priority are in conflict the definition in the present application shall control the meaning of the terms the term u201c effective amount u201d denotes an amount of an active ingredient that when administered to a subject for treating a state disorder or condition produces an intended therapeutic benefit in a subject the term u201c active ingredient u201d used interchangeably with u201c active u201d or u201c active substance u201d used herein includes melogliptin or its salts analogs derivatives polymorphs solvates single isomers enantiomers metabolites prodrugs and mixtures thereof by u201c salts u201d or u201c pharmaceutically acceptable salts u201d it is meant those salts and esters which are within the scope of sound medical judgment suitable for use in contact with the tissues of humans and lower animals without undue toxicity irritation and allergic response commensurate with a reasonable benefit to risk ratio and effective for their intended use representative acid addition salts include the hydrochloride hydrobromide sulphate bisulphate acetate oxalate valerate oleate palmitate stearate laurate borate benzoate lactate phosphate tosylate mesylate citrate maleate fumarate succinate tartrate ascorbate glucoheptonate lactobionate and lauryl sulphate salts representative alkali or alkaline earth metal salts include the sodium calcium potassium and magnesium salts in a preferred embodiment the melogliptin salt is melogliptin mesylate the term u201c treating u201d or u201c treatment u201d as used herein also covers the u201c prophylaxis u201d u201c mitigation u201d u201c prevention u201d u201c amelioration u201d or u201c suppression u201d of a disorder related to increased glucose level in a subject the term u201c.